Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0000904454-19-000079)

Filing Details

Accession Number:: 0000904454-19-000079
Form Type:: 13G Filing
Publication Date:: 2019-01-22 11:55:55

Filed By:: Johnson & Johnson
Company:: Phasebio Pharmaceuticals Inc (NASDAQ:PHAS)
Filing Date:: 2019-01-22
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Johnson Johnson EIN	0	1,616,863	0	1,616,863	1,616,863	6.6%
Johnson Johnson Innovation-JJDC, Inc. EIN	0	1,616,863	0	1,616,863	1,616,863	6.6%

Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. )¹

PhaseBio Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

717224109

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[ X ] Rule 13d-1(d)

¹ The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 717224109

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson EIN: 22-1024240
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER -0-
		6.	SHARED VOTING POWER 1,616,863*
		7.	SOLE DISPOSITIVE POWER -0-
		8.	SHARED DISPOSITIVE POWER 1,616,863*
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,616,863*
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			[ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.6%**
12.	TYPE OF REPORTING PERSON CO

* As of December 31, 2018.

** Based on 24,498,275 shares of Common Stock outstanding as of November 26, 2018, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2018 filed with the Securities and Exchange Commission on November 29, 2018.

CUSIP No. 717224109

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson Innovation-JJDC, Inc. EIN: 22-2007137
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER -0-
		6.	SHARED VOTING POWER 1,616,863*
		7.	SOLE DISPOSITIVE POWER -0-
		8.	SHARED DISPOSITIVE POWER 1,616,863*
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,616,863*
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			[ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.6%**
12.	TYPE OF REPORTING PERSON CO

* As of December 31, 2018.

CUSIP No. 717224109

SCHEDULE 13G

ITEM 1(a)		NAME OF ISSUER:

		PhaseBio Pharmaceuticals, Inc.

ITEM 1(b)		ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

		1 Great Valley Parkway, Suite 30, Malvern, PA 19355

ITEM 2(a)		NAME OF PERSON FILING:

		This statement is being filed by Johnson & Johnson, a New Jersey corporation (“J&J”), and Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation (“JJDC”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC.

ITEM 2(b)		ADDRESS OF PRINCIPAL BUSINESS OFFICE:

		J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 JJDC: 410 George Street, New Brunswick, NJ 08901

ITEM 2(c)		CITIZENSHIP:

		J&J: New Jersey
		JJDC: New Jersey

ITEM 2(d)		TITLE OF CLASS OF SECURITIES:

		Common Stock, $0.001 par value

ITEM 2(e)		CUSIP NUMBER:

		717224109

ITEM 3		STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):

		Not applicable.

ITEM 4	OWNERSHIP:

	The information set forth in the cover pages to this Schedule 13G is incorporated herein by reference thereto.

ITEM 5	OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

	Not applicable.

CUSIP No. 717224109

ITEM 6	OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

	Not applicable.

ITEM 7	IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:

	Not applicable.

ITEM 8	IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

	Not applicable.

ITEM 9	NOTICE OF DISSOLUTION OF GROUP:

	Not applicable.


ITEM 10	CERTIFICATION:

	Not applicable.

CUSIP No. 717224109

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: January 22, 2019

	JOHNSON & JOHNSON
	By:	/s/ Thomas Spellman III
	Name:	Thomas Spellman III
	Title:	Secretary


	JOHNSON & JOHNSON INNOVATION-JJDC, INC.

	By:	/s/ Kevin Norman
	Name:	Kevin Norman
	Title:	Assistant Secretary